DCE-MRI and DWI Can Differentiate Benign from Malignant Prostate Tumors when Serum PSA is ≥10 Ng/ml

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 29

PMID 36578948

Authors

Hongmei Sun

Fengli Du

Yan Liu

Qian Li

Xinai Liu

Tongming Wang

Affiliations

Soon will be listed here.

Abstract

Background: This study investigated the diagnostic utility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) parameters for distinguishing between benign and malignant prostate tumors when serum prostate-specific antigen (PSA) level is ≥10 ng/ml.

Methods: Patients with prostate cancer (PCa) and benign prostatic hyperplasia (BPH) with serum PSA ≥10 ng/ml before treatment were recruited. Transrectal ultrasound-guided biopsy or surgery was performed for tumor classification and patients were stratified accordingly into PCa and BPH groups. Patients underwent DCE-MRI and DWI scanning and the transfer constant (K), rate constant (K), fractional volume of the extravascular extracellular space, plasma volume (V), and Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2) score were determined. The apparent diffusion coefficient (ADC) was calculated from DWI. The diagnostic performance of these parameters was assessed by receiver operating characteristic (ROC) curve analysis, and those showing a significant difference between the PCa and BPH groups were combined into a multivariate logistic regression model for PCa diagnosis. Spearman's correlation was used to analyze the relationship between Gleason score and imaging parameters.

Results: The study enrolled 65 patients including 32 with PCa and 33 with BPH. Ktrans (P=0.006), Kep (P=0.001), and Vp (P=0.009) from DCE-MRI and ADC (P<0.001) from DWI could distinguish between the 2 groups when PSA was ≥10 ng/ml. PI-RADS score (area under the ROC curve [AUC]=0.705), Ktrans (AUC=0.700), Kep (AUC=0.737), Vp (AUC=0.688), and ADC (AUC=0.999) showed high diagnostic performance for discriminating PCa from BPH. A combined model based on PI-RADS score, Ktrans, Kep, Vp, and ADC had a higher AUC (1.000), with a sensitivity of 0.998 and specificity of 0.999. Imaging markers showed no significant correlation with Gleason score in PCa.

Conclusion: DCE-MRI and DWI parameters can distinguish between benign and malignant prostate tumors in patients with serum PSA ≥10 ng/ml.

References

Aminsharifi A, Howard L, Wu Y, de Hoedt A, Bailey C, Freedland S . Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. J Urol. 2018; 200(4):758-766. DOI: 10.1016/j.juro.2018.05.016. View

Oh J, Henry R, Pirzkall A, Lu Y, Li X, Catalaa I . Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. 2004; 19(5):546-54. DOI: 10.1002/jmri.20039. View

Iyama Y, Nakaura T, Katahira K, Iyama A, Nagayama Y, Oda S . Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multi-parametric prostate MRI. Eur Radiol. 2017; 27(9):3600-3608. DOI: 10.1007/s00330-017-4775-2. View

Futterer J, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A . Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015; 68(6):1045-53. DOI: 10.1016/j.eururo.2015.01.013. View

Wang M, Zeng Q, Li Y, Imani S, Xie D, Li Y . Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model and . J Drug Target. 2020; 28(9):961-969. DOI: 10.1080/1061186X.2020.1764963. View

Selnaes K, Heerschap A, Jensen L, Tessem M, Schweder G, Goa P . Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol. 2012; 47(11):624-33. DOI: 10.1097/RLI.0b013e318263f0fd. View

Welch H, Albertsen P . Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. N Engl J Med. 2020; 382(16):1557-1563. DOI: 10.1056/NEJMms1914228. View

Wu X, Reinikainen P, Kapanen M, Vierikko T, Ryymin P, Kellokumpu-Lehtinen P . Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage. Contrast Media Mol Imaging. 2018; 2018:3181258. PMC: 6169212. DOI: 10.1155/2018/3181258. View

GLEASON D, MELLINGER G . Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111(1):58-64. DOI: 10.1016/s0022-5347(17)59889-4. View

10.

Leach M, Brindle K, Evelhoch J, Griffiths J, Horsman M, Jackson A . The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer. 2005; 92(9):1599-610. PMC: 2362033. DOI: 10.1038/sj.bjc.6602550. View

11.

Othman A, Falkner F, Weiss J, Kruck S, Grimm R, Martirosian P . Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate. Invest Radiol. 2015; 51(5):290-6. DOI: 10.1097/RLI.0000000000000234. View

12.

Tofts P, Brix G, Buckley D, Evelhoch J, Henderson E, Knopp M . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999; 10(3):223-32. DOI: 10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s. View

13.

Weinreb J, Barentsz J, Choyke P, Cornud F, Haider M, Macura K . PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2015; 69(1):16-40. PMC: 6467207. DOI: 10.1016/j.eururo.2015.08.052. View

14.

Barrett T, Brechbiel M, Bernardo M, Choyke P . MRI of tumor angiogenesis. J Magn Reson Imaging. 2007; 26(2):235-49. DOI: 10.1002/jmri.20991. View

15.

Park H, Jang H, Kim S, Lee S, Won H, Byun J . Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J Hepatol. 2019; 72(4):718-724. DOI: 10.1016/j.jhep.2019.12.001. View

16.

Hu L, Zha Y, Wang L, Li L, Xing D, Gong W . Quantitative Evaluation of Vertebral Microvascular Permeability and Fat Fraction in Alloxan-induced Diabetic Rabbits. Radiology. 2017; 287(1):128-136. DOI: 10.1148/radiol.2017170760. View

17.

OConnor J, Jackson A, Parker G, Roberts C, Jayson G . Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol. 2012; 9(3):167-77. DOI: 10.1038/nrclinonc.2012.2. View

18.

Palmisano A, Di Chiara A, Esposito A, Rancoita P, Fiorino C, Passoni P . MRI prediction of pathological response in locally advanced rectal cancer: when apparent diffusion coefficient radiomics meets conventional volumetry. Clin Radiol. 2020; 75(10):798.e1-798.e11. DOI: 10.1016/j.crad.2020.06.023. View

19.

Qi Y, Zhang S, Wei J, Zhang G, Lei J, Yan W . Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies. J Magn Reson Imaging. 2019; 51(6):1890-1899. DOI: 10.1002/jmri.27008. View

20.

Ma X, Lv K, Sheng J, Yu Y, Pang P, Xu M . Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer. Oncol Lett. 2019; 17(3):3077-3084. PMC: 6396180. DOI: 10.3892/ol.2019.9988. View